Tag Archive for: Pharma

Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones

Accomplished CFO and COO with proven track record in the biotech and pharmaceutical industry Strengthens Curve’s Leadership Team following £40.5 million Series A financing Southampton, UK, 9 July 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the […]

Death cap poison: the latest weapon in the fight against cancer

The death cap mushroom is feared throughout much of the world because of the deadly toxin it contains, amanitin. But could the poison reputedly used by Agrippina to murder her husband, the Roman emperor Claudius, be used to destroy cancer, asks Richard Staines. Known to modern science as an inhibitor of RNA polymerase II, alpha-Amanitin […]

ON Helix Conference | 4th July 2024

Optimum is a proud sponsor of ON Helix. This one-day conference will address key bio innovation trends, from developments in life science and technology research to their translation into new diagnostics, prevention tools or treatments. Delegates and Supporters will connect with the One Nucleus network to explore New Horizons for Bio Innovation. ON Helix Key […]

Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation

The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that the shareholders and holders of American Depositary Shares (“ADS”) of Calliditas Therapeutics AB (publ) (jointly the “Securityholders”) accept the public tender offer by Asahi Kasei Corporation. Background This statement is made by the Board of Directors (the “Board”) of Calliditas Therapeutics AB (publ) […]

Poolbeg Pharma plc – Significant POLB 001 Patent Granted in United States

Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering 1 May 2024 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that, further to its announcement on 20 March 2024, the Company has received the fully […]